Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Tirzepatide is in a class of medications called ... As a result, “it is difficult to delineate the exact mechanism,” he says. Dr. Buettner also points out that he’s never seen this in ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Novo pioneered it in 2021 when launching Wegovy (semaglutide of GLP-1 class), and Lilly (covered by our US colleague Courtney Breen) followed up at end-2023 with Zepbound (tirzepatide, dual mechanism ...
Arrowhead (ARWR) announced presentation of preclinical data supporting the advancement of two clinical stage, RNAi-based investigational ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results